Ultragenyx Pharmaceutical's two major late-stage pipeline failures have reset investor sentiment. Find out why RARE stock is a Hold.
BASEL, Switzerland, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultra-rare genetic diseases, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) accepted on 28th October 2026 the Company’s Marketing Authorisation Application (MAA) for rebisufligene etisparvovec (also known as rebi-vec or UX111), an investigational gene therapy for the tre
Ultragenyx remains a cautious Hold as R&D cuts support profitability, while CRYSVITA concentration and pipeline setbacks cloud growth. Learn more about RARE stock here.
Ultragenyx Pharmaceutical has seen its stock lose ground over several years even as new rare disease treatments and regulatory decisions continue to reshape its outlook. With the share price recently around US$16.63 after a long slide, the live question is whether what investors are paying today lines up with the company’s current level of sales. Over the past 5 years, Ultragenyx Pharmaceutical shares have fallen 79.4%, which puts a sharper focus on whether the remaining valuation is still...
Ultragenyx Pharmaceutical (RARE) is in focus after receiving FDA approvals for its first two commercial gene therapies, GENGLYCOS and FAYUVI, while simultaneously cutting 20% of its workforce and discontinuing two development programs. The latest moves have arrived after a volatile stretch for Ultragenyx Pharmaceutical, with a 1-month share price return of 9.26%. However, a 90-day share price decline of 33.29% and a 1-year total shareholder return decline of 48.77% point to longer term...
While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
A family affected by Sanfilippo syndrome raised millions of dollars for research. The Food and Drug Administration just approved a gene therapy the support helped make possible.
After their daughter was diagnosed with a rare inherited disease in 2013, the O'Neill family raised money to find a treatment. The Food and Drug Administration recently approved a gene therapy.
Ultragenyx agrees to sell its Fayuvi-linked PRV for $203 million, marking its second voucher sale in one week and adding non-dilutive funding for rare-disease programs.
Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.
Detailed price information for Unitedhealth Group (UNH-N) from The Globe and Mail including charting and trades.
RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.
Ultragenyx Pharmaceutical (RARE) stock gains as the company inks a $210M deal to sell an FDA priority review voucher tied to recent Genglycos approval. Read more here.
RARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward formal review in Europe.
Ultragenyx shares are trading around $16 after gaining about 9% this week, rebounding from the $12.73 low hit earlier this month.
Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.
In September 2026, Ultragenyx Pharmaceutical received full U.S. FDA approval for FAYUVI (UX111), the first-ever treatment for pediatric patients with Sanfilippo syndrome Type A, along with a Priority Review Voucher. This approval not only addresses a previously untreated ultra-rare, fatal neurodegenerative disease but also expands Ultragenyx’s commercial gene therapy portfolio and manufacturing footprint in the U.S. We’ll now explore how FAYUVI’s first-in-disease approval and the associated...
This is the newest page. Registered accounts read further back.